30 closest matches · ranked by relevance
The Methodology Assessment of Glucose Dependent Insulin Secretion
Primary: Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose — 2.14; 1.49; 0.53; 2.95 (ng/min) / (mg/dL) — p=<0.001
Type 2 Diabetes Mellitus
Primary: Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose — 9.73; 8.03 ng/min — p=<0.001
Diabetes Mellitus, Type 2
Primary: Insulin Secretion — 56766 pmol/l * 90 minutes
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
Diabetes Mellitus, Type 2 · Insulin Resistance
Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001
Diabetes · Hyperglycemia
Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min
Metabolic Diseases
Primary: Oral Glucose Sensitivity Index (Kisspeptin-Placebo) — 517; 521 ml min-1m-2
Obesity
Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min
Type II Diabetes Mellitus
Primary: Change in Plasma Glucose Concentration — -29.7; -17.2; 3.1; 0.9 mg/dl
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
Healthy
Primary: Arginine-stimulated Insulin Secretion With and Without GLP-1 Blockade — 320.1; 243.4; 280; 251.2 pmol/L — p=< 0.05
Type 2 Diabetes
Primary: Glucagon Counterregulation to Hypoglycemia — 16.0; 16.5 pmol/l
Type 1 Diabetes
Primary: Effectiveness of Closed Loop Diabetes Control — 136.9; 149.5 mg/dl
Type 1 Diabetes · Type 1 Diabetes Mellitus With Hypoglycemia · Hypoglycemia
Primary: The Change in Plasma Glucagon Levels (Pmol/L) Measured During Normoglycaemic and Hypoglycaemia — 1.34; 1.68; 2.26; 0.31 pmol/L — p=>0.99
Pre-diabetes · Type 2 Diabetes
Primary: Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml) — 214; 149; 133; 188.5 μU/ml — p==0.1
Type 1 Diabetes
Primary: Percentage of Time in Target Range Over 24 Hour — 2; 4.7; 1.3 percentage of time
Healthy
Primary: Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion — 191; 171 nmol/min per 300 min — p=0.02
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005
Diabetes
Primary: Peak Epinephrine Levels — 609 pg/mL
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
Insulin Secretion · Insulin Resistance
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.08 percentage
Diabetes Mellitus, Type 2
Primary: Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment — -0.18; 0.14; -0.08; -0.03 mg/kg.min
Healthy
Primary: Endogenous Glucose Production (EGP) — 4.99; 5.02; 6.82; 5.52 umol/kg/min
Gestational Diabetes · Diabetes, Gestational · Pregnancy in Diabetes
Primary: Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study — 25; 26 Participants — p=0.9
Healthy Volunteers
Primary: Glycemic Index — 100; 33.68; 12.83 % of GI of the glucose
Diabetes Mellitus, Type 1
Primary: Change Between Pre and Post Challenge Glucose Variability — 0.51; 1.62; 3.71; 0.97 score on a scale
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
Chronic Kidney Diseases · Type 2 Diabetes
Primary: Glucose Time in Range — 495.2; 573.3 minutes per day
Type 2 Diabetes Mellitus
Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05
Hypoglycemia
Primary: Time to Reach 50% of Maximum Glucose Concentration (Glucose T50%-Early) — 17.2; 21.9; 21.3; 7.6 minutes — p=0.23